Teacher Retirement System of Texas Purchases 1,626 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Teacher Retirement System of Texas boosted its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 14.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,945 shares of the biotechnology company's stock after purchasing an additional 1,626 shares during the quarter. Teacher Retirement System of Texas' holdings in United Therapeutics were worth $4,568,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Wealthfront Advisers LLC boosted its position in shares of United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after buying an additional 18,313,424 shares during the period. Geode Capital Management LLC boosted its position in United Therapeutics by 4.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company's stock worth $391,459,000 after acquiring an additional 45,566 shares during the period. FMR LLC grew its stake in shares of United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock worth $386,168,000 after purchasing an additional 314,004 shares in the last quarter. Pacer Advisors Inc. increased its holdings in shares of United Therapeutics by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company's stock valued at $210,869,000 after purchasing an additional 30,931 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in United Therapeutics by 12.3% in the third quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company's stock worth $164,978,000 after purchasing an additional 50,409 shares during the period. Institutional investors own 94.08% of the company's stock.

Remove Ads

United Therapeutics Stock Down 1.0 %

Shares of NASDAQ UTHR traded down $3.13 during mid-day trading on Tuesday, hitting $316.73. 345,532 shares of the company traded hands, compared to its average volume of 445,356. United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82. The stock has a market capitalization of $14.22 billion, a price-to-earnings ratio of 13.91, a PEG ratio of 0.97 and a beta of 0.64. The business has a 50 day moving average of $344.24 and a two-hundred day moving average of $356.84.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the prior year, the firm earned $4.36 earnings per share. As a group, research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Buying and Selling

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares of the company's stock, valued at $1,966,696.56. The trade was a 4.41 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $956,195.85. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,755 shares of company stock valued at $29,792,021. Company insiders own 11.90% of the company's stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. Finally, UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and an average price target of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.